Expensify And 2 Other Stocks Under $2 Insiders Are Buying
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
Expsify 和 2 個低於 2 美元的股票，內部人們正在購買
The Dow Jones index closed lower by over 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週一收跌逾100點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對於有興趣投資或交易低價股票的投資者和交易者來說，他們可以考慮這一因素作爲整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。
Expensify
Expensify
- The Trade: Expensify, Inc. (NASDAQ:EXFY) Director Timothy L Christen bought a total of 19,162 shares at an average price of $1.61. To acquire these shares, it cost around $30,851.
- What's Happening: On May 9, Expensify posted downbeat quarterly results.
- What Expensify Does: Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money.
- 交易：Expensify, Inc.（納斯達克:EXFY）董事Timothy L Christen以平均價格1.61美元購買了總共19162股。購買這些股票，花費大約30851美元。
- 現在發生了什麼：5月9日，Expensify發佈了令人沮喪的季度業績。
- Expensify Inc是一家基於雲的費用管理軟件平台，可以幫助各種企業簡化財務管理。
Bio Essence
Bio Essence
- The Trade: Bio Essence Corporation (OTC:BIOE) CEO Yin Yan acquired a total of 5,000,000 shares at an average price of $0.50. To acquire these shares, it cost around $2.5 million.
- What's Happening: The company's stock jumped around 127% over the past month.
- What Bio Essence Does: Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements.
- 交易：Bio Essence Corporation（場外交易:BIOE）首席執行官Yin Yan以平均價格0.50美元收購了總共500萬股。購買這些股票，花費大約250萬美元。
- 現在發生了什麼：該公司的股票在過去一個月中暴漲了約127％。
- Bio Essence Corp是一家草藥保健，飲食和營養公司。該公司的使命是提供草藥保健，飲食和維生素營養補充劑。
Perspective Therapeutics
Perspective Therapeutics
- The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CFO Jonathan Robert Hunt acquired a total of 25,006 shares at an average price of $1.40. The insider spent around $35,007 to buy those shares. The company's Director Robert F Williamson III also bought 55,000 shares of the company.
- What's Happening: On May 24, Perspective Therapeutics announced the pricing of $80 million underwritten offering of common stock and pre-funded warrants.
- What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.
- 交易：Perspective Therapeutics, Inc.（納斯達克：CATX）首席財務官Jonathan Robert Hunt以平均價格1.40美元收購了總共25006股。這位內部人士花費大約35,007美元購買了這些股票。該公司的董事Robert F Williamson III也購買了該公司的55000股股票。
- 現在發生了什麼：5月24日，Perspective Therapeutics宣佈定價8000萬美元的普通股和預售認股權的認購發行。
- Perspective Therapeutics Inc是一家醫療技術和放射性製劑公司，正在開發治療全身各種癌症的各種治療應用。
Now Read This: Top 3 Utilities Stocks That May Plunge In Q2
現在閱讀這篇文章：可能在第二季度暴跌的前3只公用事業股票
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間